<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01515696</url>
  </required_header>
  <id_info>
    <org_study_id>27112001</org_study_id>
    <secondary_id>2007-000851-33</secondary_id>
    <nct_id>NCT01515696</nct_id>
  </id_info>
  <brief_title>Impact of Oral Application of Gastrografin on the Meconium Evacuation in Very Low Birth Weight Infants</brief_title>
  <official_title>Impact of Oral Application of Gastrografin on the Meconium Evacuation in Very Low Birth Weight Infants- a Phase 4 Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nadja Haiden,MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Vienna</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Gastrografin is a radiopaque contrast agent for the gastrointestinal tract (GIT) which can be
      applied orally or rectally. In neonatal intensive care, Gastrografin is used to detect
      otherwise radiologically invisible perforations or an insufficient GIT anastomosis after
      surgery. Furthermore it is used for the treatment of meconium ileus. Gastrografin has a
      strong osmotic effect and leads to water influx into the intestine lumen. Thereby the
      peristaltic movement is accelerated and the premature infant excretes stool during the hours
      following application. Therefore Gastrografin might be effective to mobilize meconium from
      small bowel and deep parts of the colon. The investigators hypothesized that enteral
      application of Gastrografin accelerates meconium evacuation in premature infants, and thereby
      enhances feeding tolerance in this population.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In premature infants the establishment of proper gastrointestinal function is challenging and
      often associated with delayed meconium passage. Meconium evacuation depends on gestational
      age and birthweight: the more immature an infant is, the later meconium passage starts and
      the longer meconium passage lasts. The mean duration of meconium evacuation in premature
      infants with a gestational age below 30 weeks is 8 days, while mature infants excrete their
      meconium in 2 days. The obstruction of deep intestinal segments by tenacious, sticky meconium
      frequently leads to gastric residuals, a distended abdomen and delayed food passage. The time
      lag to full enteral feedings is extended, the probability to acquire infections due to
      intravenous access for parenteral nutrition increases and the hospital stay of the infant is
      prolonged. However, the relation between meconium passage and feeding tolerance remains
      controversial. While one study showed that there is little concordance between first meconium
      passage and feeding tolerance, an other one showed that rapid and complete excretion of
      meconium is crucial for oral feeding tolerance and has a positive effect on it. Recently, the
      investigators performed a prospective randomized trial to determine, whether repeated
      prophylactic applications of small volume glycerin enemas accelerate passage of meconium in
      very low birth weight (VLBW) infants. Disappointingly, application of enemas did not
      accelerate meconium evacuation. A possible reason for the ineffectiveness of glycerin enemas
      is that the volume used was too small to mobilize tenacious meconium sufficiently from the
      colon and small bowel.

      Gastrografin is a radiopaque contrast agent for the gastrointestinal tract (GIT) which can be
      applied orally or rectally. In neonatal intensive care, Gastrografin is used to detect
      otherwise radiologically invisible perforations or an insufficient GIT anastomosis after
      surgery. Furthermore it is used for the treatment of meconium ileus. Gastrografin has a
      strong osmotic effect and leads to water influx into the intestine lumen. Thereby the
      peristaltic movement is accelerated and the premature infant excretes stool during the hours
      following application. Therefore Gastrografin might be more effective to mobilize meconium
      from small bowel and deep parts of the colon. The investigators hypothesized, that enteral
      application of Gastrografin accelerates meconium evacuation in premature infants, and thereby
      enhances feeding tolerance in this population. The objective of the present study is to
      determine whether the enteral application of the osmotic contrast agent GastrografinÂ®
      accelerates complete meconium excretion and improves feeding tolerance in very low birth
      weight infants.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2007</start_date>
  <completion_date type="Actual">February 2011</completion_date>
  <primary_completion_date type="Actual">October 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to Complete Meconium Evacuation in Days</measure>
    <time_frame>days of life until until the complete meconium evacuation from birth up to 40 days of life</time_frame>
    <description>Time to complete meconium evacuation in days of life until the complete meconium evacuation from birth up to 40 days of life</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Feeding Tolerance- Full Enteral Feedings</measure>
    <time_frame>days of life from birth until an infant tolerates en enteral feeding volume of 140 ml/kg</time_frame>
    <description>full enteral feeding is defined in days of life from birth until an an infant tolerates an enteral feeding volume of 140ml/kg</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">96</enrollment>
  <condition>Meconium Ileus</condition>
  <condition>Very Low Birth Weight Infant</condition>
  <arm_group>
    <arm_group_label>Gastrografin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>infants receive 3ml/kg Gastrografin + 6ml/kg sterile water</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sterile water</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>infants receive 9ml/kg sterile water</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gastrografin</intervention_name>
    <description>Patients will receive 3ml Gastrografin + 6ml sterile water/kg as a single dose via a nasogastric tube during the first 24 hours of life.</description>
    <arm_group_label>Gastrografin</arm_group_label>
    <other_name>Diatrizoate Meglumine, Diatrizoate Sodium</other_name>
    <other_name>NDA-011245</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sterile water</intervention_name>
    <description>Patients will receive 9ml/kg sterile water as a single dose via a nasogastric tube during the first 24 hours of life.</description>
    <arm_group_label>Sterile water</arm_group_label>
    <other_name>Sterile water (ANDA) #077393</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  premature infants with a birthweight &lt; 1500g and a gestational age &lt; 32 weeks

        Exclusion Criteria:

          -  major congenital disorders

          -  chromosomal aberrations

          -  systemic metabolic disease and

          -  pre-existing gastrointestinal abnormalities (i.e. Morbus Hirschsprung)

          -  pre-existing conditions of severe hypotension
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>24 Hours</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nadja Haiden, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical university of Vienna, Department of Pediatrics</affiliation>
  </overall_official>
  <verification_date>June 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 10, 2012</study_first_submitted>
  <study_first_submitted_qc>January 23, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 24, 2012</study_first_posted>
  <results_first_submitted>October 29, 2013</results_first_submitted>
  <results_first_submitted_qc>June 17, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 18, 2014</results_first_posted>
  <last_update_submitted>June 17, 2014</last_update_submitted>
  <last_update_submitted_qc>June 17, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 18, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Vienna</investigator_affiliation>
    <investigator_full_name>Nadja Haiden,MD</investigator_full_name>
    <investigator_title>Assoc.Prof.MD.</investigator_title>
  </responsible_party>
  <keyword>VLBW infant</keyword>
  <keyword>Meconium</keyword>
  <keyword>Enteral nutrition</keyword>
  <keyword>Meconium passage</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Body Weight</mesh_term>
    <mesh_term>Birth Weight</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>3 year study period 789 infants were eligible for enrollment in the study</recruitment_details>
      <pre_assignment_details>Six hundred ninety-three infants were excluded for the following reasons: informed consent was not obtained in time(n = 660), parental refusal (n = 21), and 12 infants died before randomization.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Gastrografin</title>
          <description>infants received 3ml/kg Gastrografin + 6ml/kg sterile water once during the first 24 hours of life via gastric tube</description>
        </group>
        <group group_id="P2">
          <title>Sterile Water</title>
          <description>infants received 9ml/kg sterile water once during the first 24 hours of life via gastric tube</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="47"/>
                <participants group_id="P2" count="49"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="39"/>
                <participants group_id="P2" count="39"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Gastrografin</title>
          <description>infants receive 3ml/kg Gastrografin + 6ml/kg sterile water</description>
        </group>
        <group group_id="B2">
          <title>Sterile Water</title>
          <description>infants receive 9ml/kg sterile water</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="47"/>
            <count group_id="B2" value="49"/>
            <count group_id="B3" value="96"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                    <measurement group_id="B2" value="49"/>
                    <measurement group_id="B3" value="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Austria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                    <measurement group_id="B2" value="49"/>
                    <measurement group_id="B3" value="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>birthweight</title>
          <units>grams</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="870" spread="0" lower_limit="490" upper_limit="1440"/>
                    <measurement group_id="B2" value="900" spread="0" lower_limit="480" upper_limit="1414"/>
                    <measurement group_id="B3" value="879" spread="0" lower_limit="480" upper_limit="1440"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Time to Complete Meconium Evacuation in Days</title>
        <description>Time to complete meconium evacuation in days of life until the complete meconium evacuation from birth up to 40 days of life</description>
        <time_frame>days of life until until the complete meconium evacuation from birth up to 40 days of life</time_frame>
        <population>per protocol</population>
        <group_list>
          <group group_id="O1">
            <title>Gastrografin</title>
            <description>infants receive 3ml/kg Gastrografin + 6ml/kg sterile water</description>
          </group>
          <group group_id="O2">
            <title>Sterile Water</title>
            <description>infants receive 9ml/kg sterile water</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Complete Meconium Evacuation in Days</title>
          <description>Time to complete meconium evacuation in days of life until the complete meconium evacuation from birth up to 40 days of life</description>
          <population>per protocol</population>
          <units>days of life</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7" lower_limit="3" upper_limit="16"/>
                    <measurement group_id="O2" value="8" lower_limit="1" upper_limit="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.61</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Median Difference (Net)</param_type>
            <param_value>1</param_value>
            <ci_percent>95</ci_percent>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Feeding Tolerance- Full Enteral Feedings</title>
        <description>full enteral feeding is defined in days of life from birth until an an infant tolerates an enteral feeding volume of 140ml/kg</description>
        <time_frame>days of life from birth until an infant tolerates en enteral feeding volume of 140 ml/kg</time_frame>
        <population>per protocol</population>
        <group_list>
          <group group_id="O1">
            <title>Gastrografin</title>
            <description>infants receive 3ml/kg Gastrografin + 6ml/kg sterile water</description>
          </group>
          <group group_id="O2">
            <title>Sterile Water</title>
            <description>infants receive 9ml/kg sterile water</description>
          </group>
        </group_list>
        <measure>
          <title>Feeding Tolerance- Full Enteral Feedings</title>
          <description>full enteral feeding is defined in days of life from birth until an an infant tolerates an enteral feeding volume of 140ml/kg</description>
          <population>per protocol</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19" lower_limit="10" upper_limit="68"/>
                    <measurement group_id="O2" value="26.5" lower_limit="9" upper_limit="109"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.05</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>7.5</param_value>
            <ci_percent>95</ci_percent>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Necrotizing Enterocolitis</title>
        <description>necrotizing enterocolitis stage 2a after Bell</description>
        <time_frame>End of study</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Gastrografin</title>
            <description>infants receive 3ml/kg Gastrografin + 6ml/kg sterile water</description>
          </group>
          <group group_id="O2">
            <title>Sterile Water</title>
            <description>infants receive 9ml/kg sterile water</description>
          </group>
        </group_list>
        <measure>
          <title>Necrotizing Enterocolitis</title>
          <description>necrotizing enterocolitis stage 2a after Bell</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>from birth until discharge of the infant with a maximum of 5 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Gastrografin</title>
          <description>infants receive 3ml/kg Gastrografin + 6ml/kg sterile water</description>
        </group>
        <group group_id="E2">
          <title>Sterile Water</title>
          <description>infants receive 9ml/kg sterile water</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="42" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>persistent ductus arteriosus</sub_title>
                <counts group_id="E1" events="22" subjects_affected="22" subjects_at_risk="47"/>
                <counts group_id="E2" events="28" subjects_affected="28" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>death</sub_title>
                <description>death because of immaturity and associated complications like multiple organ failure</description>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="47"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>necrotizing enterocolitis</sub_title>
                <description>necrotizing enterocolitis stage II or more according to Bell</description>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="47"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>intraventricular haemorrhage</sub_title>
                <description>intraventricular haemorrhage grade 3 and 4 according the definition of papillae et al</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="47"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>culture proven sepsis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="47"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Nadja Haiden M.D.</name_or_title>
      <organization>Medical University of Vienna</organization>
      <phone>+431404003232</phone>
      <email>nadja.haiden@meduniwien.ac.at</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

